

Roberto Ranza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5676543/publications.pdf>

Version: 2024-02-01

15
papers

299
citations

1163117

8
h-index

1125743

13
g-index

15
all docs

15
docs citations

15
times ranked

415
citing authors

#	ARTICLE	IF	CITATIONS
1	Registro brasileiro de biológicos: processo de implementação e resultados preliminares do BiobadaBrasil. Revista Brasileira De Reumatologia, 2011, 51, 152-160.	0.8	59
2	Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review. Journal of Rheumatology, 2014, 41, 2277-2285.	2.0	51
3	Prevalence of Psoriatic Arthritis in a Large Cohort of Brazilian Patients with Psoriasis. Journal of Rheumatology, 2015, 42, 829-834.	2.0	39
4	Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL. Clinical Rheumatology, 2015, 34, 921-927.	2.2	35
5	Incidência de tuberculose em pacientes com artrite reumatoide em uso de bloqueadores do TNF no Brasil: dados do Registro Brasileiro de Monitoração de Terapias Biológicas BiobadaBrasil. Revista Brasileira De Reumatologia, 2017, 57, 477-483.	0.8	28
6	Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 54 477-483.	0.7	19
7	Brazilian biologic registry: BiobadaBrasil implementation process and preliminary results. Revista Brasileira De Reumatologia, 2011, 51, 152-60.	0.8	16
8	Incidence of Infectious Adverse Events in Patients With Rheumatoid Arthritis and Spondyloarthritis on Biologic Drugs Data From the Brazilian Registry for Biologics Monitoring. Journal of Clinical Rheumatology, 2020, 26, 73-78.	0.9	11
9	Esophageal manometry in systemic sclerosis: findings and association with clinical manifestations. Revista Da Associação Médica Brasileira, 2020, 66, 48-54.	0.7	10
10	Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR. Clinical Rheumatology, 2019, 38, 2129-2139.	2.2	8
11	Safety of the Methotrexate-leflunomide Combination in Rheumatoid Arthritis: Results of a Multicentric, Registry-based, Cohort Study (BiobadaBrasil). Journal of Rheumatology, 2021, 48, 1519-1527.	2.0	8
12	Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2. Rheumatology and Therapy, 2021, 8, 1827-1844.	2.3	8
13	Semantic and psychometric validation of the Brazilian Portuguese version (PASE-P) of the Psoriatic Arthritis Screening and Evaluation questionnaire. PLoS ONE, 2018, 13, e0205486.	2.5	6
14	Clinical Specialty Setting as Determinant of Management of Psoriatic Arthritis. Journal of Clinical Rheumatology, 2022, 28, 120-125.	0.9	1
15	Oxaliplatin (IXE) vs. adalimumab (ADA) for the treatment of PSA: 52-week efficacy and safety outcomes. Rheumatology, 2020, 59, .	1.9	0